nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—NQO2—breast cancer	0.106	0.256	CbGaD
Imatinib—CSF1R—breast cancer	0.0716	0.173	CbGaD
Imatinib—ABL1—breast cancer	0.0557	0.134	CbGaD
Imatinib—KIT—breast cancer	0.0447	0.108	CbGaD
Imatinib—CA9—breast cancer	0.0429	0.104	CbGaD
Imatinib—SLC47A1—Mitoxantrone—breast cancer	0.0302	0.105	CbGbCtD
Imatinib—ABCG2—breast cancer	0.0247	0.0597	CbGaD
Imatinib—PTGS1—breast cancer	0.0212	0.0511	CbGaD
Imatinib—CYP2D6—breast cancer	0.0144	0.0348	CbGaD
Imatinib—CYP3A4—breast cancer	0.0124	0.0298	CbGaD
Imatinib—ALB—breast cancer	0.0108	0.026	CbGaD
Imatinib—ABCB1—breast cancer	0.0103	0.0248	CbGaD
Imatinib—CYP1A2—Anastrozole—breast cancer	0.00873	0.0302	CbGbCtD
Imatinib—CYP1A2—Toremifene—breast cancer	0.00798	0.0277	CbGbCtD
Imatinib—CYP2C9—Anastrozole—breast cancer	0.00786	0.0272	CbGbCtD
Imatinib—CYP3A5—Lapatinib—breast cancer	0.00782	0.0271	CbGbCtD
Imatinib—ABCG2—Tamoxifen—breast cancer	0.00707	0.0245	CbGbCtD
Imatinib—ABCB1—Toremifene—breast cancer	0.00698	0.0242	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—breast cancer	0.0069	0.0239	CbGbCtD
Imatinib—SLC22A2—Vinblastine—breast cancer	0.00654	0.0227	CbGbCtD
Imatinib—CYP2C19—Lapatinib—breast cancer	0.00631	0.0219	CbGbCtD
Imatinib—CYP3A4—Exemestane—breast cancer	0.00603	0.0209	CbGbCtD
Imatinib—CYP2C9—Idarubicin—breast cancer	0.00596	0.0207	CbGbCtD
Imatinib—ABCG2—Paclitaxel—breast cancer	0.0055	0.0191	CbGbCtD
Imatinib—CYP2D6—Idarubicin—breast cancer	0.00545	0.0189	CbGbCtD
Imatinib—ABCG2—Irinotecan—breast cancer	0.00543	0.0188	CbGbCtD
Imatinib—CYP3A7—Tamoxifen—breast cancer	0.00522	0.0181	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.00522	0.0181	CbGbCtD
Imatinib—ABCG2—Fluorouracil—breast cancer	0.00521	0.0181	CbGbCtD
Imatinib—ABCG2—Carboplatin—breast cancer	0.00518	0.0179	CbGbCtD
Imatinib—CYP3A4—Letrozole—breast cancer	0.00513	0.0178	CbGbCtD
Imatinib—ABCB1—Lapatinib—breast cancer	0.00509	0.0176	CbGbCtD
Imatinib—CYP3A4—Anastrozole—breast cancer	0.00457	0.0158	CbGbCtD
Imatinib—CYP3A4—Toremifene—breast cancer	0.00418	0.0145	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00407	0.0141	CbGbCtD
Imatinib—CYP3A7—Paclitaxel—breast cancer	0.00407	0.0141	CbGbCtD
Imatinib—CYP3A7—Irinotecan—breast cancer	0.00401	0.0139	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00401	0.0139	CbGbCtD
Imatinib—ABCG2—Docetaxel—breast cancer	0.00398	0.0138	CbGbCtD
Imatinib—CYP3A5—Tamoxifen—breast cancer	0.00392	0.0136	CbGbCtD
Imatinib—CYP3A4—Fulvestrant—breast cancer	0.00389	0.0135	CbGbCtD
Imatinib—ALB—Irinotecan—breast cancer	0.00374	0.013	CbGbCtD
Imatinib—ALB—Fluorouracil—breast cancer	0.00359	0.0124	CbGbCtD
Imatinib—CYP3A4—Thiotepa—breast cancer	0.00347	0.012	CbGbCtD
Imatinib—CYP2C9—Capecitabine—breast cancer	0.00327	0.0113	CbGbCtD
Imatinib—CYP3A4—Ixabepilone—breast cancer	0.00317	0.011	CbGbCtD
Imatinib—CYP2C19—Tamoxifen—breast cancer	0.00316	0.0109	CbGbCtD
Imatinib—CYP3A4—Lapatinib—breast cancer	0.00305	0.0106	CbGbCtD
Imatinib—CYP3A5—Paclitaxel—breast cancer	0.00305	0.0106	CbGbCtD
Imatinib—CYP3A5—Irinotecan—breast cancer	0.00301	0.0104	CbGbCtD
Imatinib—ABCG2—Doxorubicin—breast cancer	0.00297	0.0103	CbGbCtD
Imatinib—CYP3A7—Docetaxel—breast cancer	0.00294	0.0102	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00294	0.0102	CbGbCtD
Imatinib—CYP1A2—Tamoxifen—breast cancer	0.00292	0.0101	CbGbCtD
Imatinib—ABCG2—Methotrexate—breast cancer	0.00287	0.00996	CbGbCtD
Imatinib—ABCB1—Vinorelbine—breast cancer	0.00282	0.00979	CbGbCtD
Imatinib—CYP2D6—Vinorelbine—breast cancer	0.00266	0.00922	CbGbCtD
Imatinib—CYP2C9—Tamoxifen—breast cancer	0.00263	0.0091	CbGbCtD
Imatinib—ABCB1—Tamoxifen—breast cancer	0.00255	0.00883	CbGbCtD
Imatinib—ABCB1—Mitoxantrone—breast cancer	0.00249	0.00862	CbGbCtD
Imatinib—CYP2D6—Tamoxifen—breast cancer	0.0024	0.00832	CbGbCtD
Imatinib—CYP3A4—Raloxifene—breast cancer	0.00231	0.00801	CbGbCtD
Imatinib—CYP3A5—Docetaxel—breast cancer	0.0022	0.00764	CbGbCtD
Imatinib—ABCB1—Gemcitabine—breast cancer	0.0022	0.00761	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—breast cancer	0.00215	0.00745	CbGbCtD
Imatinib—CYP2C9—Paclitaxel—breast cancer	0.00205	0.00709	CbGbCtD
Imatinib—ABCB1—Paclitaxel—breast cancer	0.00198	0.00688	CbGbCtD
Imatinib—ALB—Methotrexate—breast cancer	0.00198	0.00686	CbGbCtD
Imatinib—ABCB1—Irinotecan—breast cancer	0.00196	0.00678	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—breast cancer	0.00194	0.00671	CbGbCtD
Imatinib—ABCB1—Vinblastine—breast cancer	0.00174	0.00603	CbGbCtD
Imatinib—CYP3A4—Vinorelbine—breast cancer	0.00169	0.00586	CbGbCtD
Imatinib—CYP2D6—Vinblastine—breast cancer	0.00164	0.00568	CbGbCtD
Imatinib—CYP3A4—Tamoxifen—breast cancer	0.00153	0.00529	CbGbCtD
Imatinib—CYP3A4—Mitoxantrone—breast cancer	0.00149	0.00516	CbGbCtD
Imatinib—ABCB1—Docetaxel—breast cancer	0.00143	0.00497	CbGbCtD
Imatinib—CYP3A4—Paclitaxel—breast cancer	0.00119	0.00412	CbGbCtD
Imatinib—CYP3A4—Irinotecan—breast cancer	0.00117	0.00406	CbGbCtD
Imatinib—ABCB1—Doxorubicin—breast cancer	0.00107	0.00371	CbGbCtD
Imatinib—CYP3A4—Vinblastine—breast cancer	0.00104	0.00361	CbGbCtD
Imatinib—DDR1—nipple—breast cancer	0.00104	0.0214	CbGeAlD
Imatinib—ABCB1—Methotrexate—breast cancer	0.00104	0.00359	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—breast cancer	0.00101	0.00349	CbGbCtD
Imatinib—CYP3A4—Docetaxel—breast cancer	0.00086	0.00298	CbGbCtD
Imatinib—PIP4K2C—mammary gland—breast cancer	0.000774	0.016	CbGeAlD
Imatinib—ABCA3—endometrium—breast cancer	0.000679	0.014	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—breast cancer	0.000641	0.00222	CbGbCtD
Imatinib—PIP4K2C—nipple—breast cancer	0.00064	0.0132	CbGeAlD
Imatinib—DDR1—endometrium—breast cancer	0.000626	0.0129	CbGeAlD
Imatinib—ABCA3—pituitary gland—breast cancer	0.000614	0.0127	CbGeAlD
Imatinib—ABCA3—adipose tissue—breast cancer	0.000612	0.0126	CbGeAlD
Imatinib—DDR1—uterus—breast cancer	0.000577	0.0119	CbGeAlD
Imatinib—HIPK4—female reproductive system—breast cancer	0.000569	0.0117	CbGeAlD
Imatinib—LCK—nipple—breast cancer	0.000568	0.0117	CbGeAlD
Imatinib—PDGFRA—mammary gland—breast cancer	0.000567	0.0117	CbGeAlD
Imatinib—DDR1—pituitary gland—breast cancer	0.000567	0.0117	CbGeAlD
Imatinib—DDR1—adipose tissue—breast cancer	0.000564	0.0116	CbGeAlD
Imatinib—Nilotinib—EPHB4—breast cancer	0.000561	0.14	CrCbGaD
Imatinib—ABCA3—adrenal gland—breast cancer	0.000549	0.0113	CbGeAlD
Imatinib—ABCA3—female gonad—breast cancer	0.000512	0.0105	CbGeAlD
Imatinib—DDR1—adrenal gland—breast cancer	0.000506	0.0104	CbGeAlD
Imatinib—CSF1R—mammary gland—breast cancer	0.000499	0.0103	CbGeAlD
Imatinib—HIPK4—endocrine gland—breast cancer	0.000481	0.00992	CbGeAlD
Imatinib—DDR1—female gonad—breast cancer	0.000472	0.00973	CbGeAlD
Imatinib—NQO2—nipple—breast cancer	0.00047	0.00969	CbGeAlD
Imatinib—KIT—mammary gland—breast cancer	0.000453	0.00934	CbGeAlD
Imatinib—ABL1—Topotecan—Irinotecan—breast cancer	0.00045	0.257	CbGdCrCtD
Imatinib—PDGFRB—mammary gland—breast cancer	0.000443	0.00912	CbGeAlD
Imatinib—CSF1R—nipple—breast cancer	0.000413	0.00851	CbGeAlD
Imatinib—ABL1—mammary gland—breast cancer	0.000395	0.00813	CbGeAlD
Imatinib—PDGFRA—embryo—breast cancer	0.000387	0.00798	CbGeAlD
Imatinib—PIP4K2C—endometrium—breast cancer	0.000387	0.00797	CbGeAlD
Imatinib—SLC47A1—nipple—breast cancer	0.000377	0.00777	CbGeAlD
Imatinib—KIT—nipple—breast cancer	0.000375	0.00773	CbGeAlD
Imatinib—Nilotinib—MAPK8—breast cancer	0.000375	0.0936	CrCbGaD
Imatinib—ABL2—pituitary gland—breast cancer	0.00037	0.00762	CbGeAlD
Imatinib—ABL2—adipose tissue—breast cancer	0.000368	0.00759	CbGeAlD
Imatinib—PDGFRB—nipple—breast cancer	0.000366	0.00755	CbGeAlD
Imatinib—Ponatinib—FGFR1—breast cancer	0.000365	0.0913	CrCbGaD
Imatinib—Ponatinib—FGFR2—breast cancer	0.000365	0.0913	CrCbGaD
Imatinib—ALB—mammary gland—breast cancer	0.000364	0.00751	CbGeAlD
Imatinib—PIP4K2C—pituitary gland—breast cancer	0.00035	0.00721	CbGeAlD
Imatinib—PIP4K2C—adipose tissue—breast cancer	0.000348	0.00718	CbGeAlD
Imatinib—CSF1R—embryo—breast cancer	0.000341	0.00702	CbGeAlD
Imatinib—CA3—uterus—breast cancer	0.00034	0.00701	CbGeAlD
Imatinib—CA3—pituitary gland—breast cancer	0.000334	0.00688	CbGeAlD
Imatinib—CA3—adipose tissue—breast cancer	0.000333	0.00686	CbGeAlD
Imatinib—ABL2—adrenal gland—breast cancer	0.00033	0.00681	CbGeAlD
Imatinib—ABCA3—lymph node—breast cancer	0.000329	0.00678	CbGeAlD
Imatinib—ABL1—nipple—breast cancer	0.000326	0.00673	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—breast cancer	0.00032	0.0066	CbGeAlD
Imatinib—LCK—uterus—breast cancer	0.000316	0.00652	CbGeAlD
Imatinib—PIP4K2C—adrenal gland—breast cancer	0.000312	0.00644	CbGeAlD
Imatinib—KIT—embryo—breast cancer	0.000309	0.00638	CbGeAlD
Imatinib—LCK—adipose tissue—breast cancer	0.000309	0.00637	CbGeAlD
Imatinib—ABL2—female gonad—breast cancer	0.000308	0.00635	CbGeAlD
Imatinib—DDR1—lymph node—breast cancer	0.000303	0.00625	CbGeAlD
Imatinib—PIP4K2C—bone marrow—breast cancer	0.000302	0.00623	CbGeAlD
Imatinib—PDGFRB—embryo—breast cancer	0.000302	0.00623	CbGeAlD
Imatinib—CA9—female reproductive system—breast cancer	0.000293	0.00603	CbGeAlD
Imatinib—PIP4K2C—female gonad—breast cancer	0.000291	0.00601	CbGeAlD
Imatinib—CA3—bone marrow—breast cancer	0.000289	0.00595	CbGeAlD
Imatinib—NQO2—endometrium—breast cancer	0.000284	0.00585	CbGeAlD
Imatinib—LCK—adrenal gland—breast cancer	0.000277	0.00572	CbGeAlD
Imatinib—PIP4K2C—endocrine gland—breast cancer	0.000271	0.00558	CbGeAlD
Imatinib—CA14—adrenal gland—breast cancer	0.000271	0.00558	CbGeAlD
Imatinib—ABL1—embryo—breast cancer	0.000269	0.00555	CbGeAlD
Imatinib—LCK—bone marrow—breast cancer	0.000268	0.00553	CbGeAlD
Imatinib—CSF1R—skin of body—breast cancer	0.000264	0.00545	CbGeAlD
Imatinib—NQO2—uterus—breast cancer	0.000262	0.00539	CbGeAlD
Imatinib—PDGFRA—uterus—breast cancer	0.000261	0.00538	CbGeAlD
Imatinib—CA3—endocrine gland—breast cancer	0.000259	0.00533	CbGeAlD
Imatinib—LCK—female gonad—breast cancer	0.000259	0.00533	CbGeAlD
Imatinib—Ponatinib—ABL1—breast cancer	0.000257	0.0643	CrCbGaD
Imatinib—NQO2—pituitary gland—breast cancer	0.000257	0.00529	CbGeAlD
Imatinib—NQO2—adipose tissue—breast cancer	0.000256	0.00527	CbGeAlD
Imatinib—PDGFRA—adipose tissue—breast cancer	0.000255	0.00526	CbGeAlD
Imatinib—KIT—epithelium—breast cancer	0.000252	0.0052	CbGeAlD
Imatinib—CSF1R—endometrium—breast cancer	0.000249	0.00514	CbGeAlD
Imatinib—CA9—endocrine gland—breast cancer	0.000248	0.00511	CbGeAlD
Imatinib—PDGFRB—epithelium—breast cancer	0.000247	0.00508	CbGeAlD
Imatinib—Nilotinib—CSF1R—breast cancer	0.000244	0.061	CrCbGaD
Imatinib—KIT—skin of body—breast cancer	0.00024	0.00495	CbGeAlD
Imatinib—NQO2—female reproductive system—breast cancer	0.000235	0.00485	CbGeAlD
Imatinib—PDGFRA—female reproductive system—breast cancer	0.000235	0.00483	CbGeAlD
Imatinib—PDGFRB—skin of body—breast cancer	0.000235	0.00483	CbGeAlD
Imatinib—Ponatinib—SRC—breast cancer	0.000233	0.0582	CrCbGaD
Imatinib—ABL1—Epirubicin—Idarubicin—breast cancer	0.000231	0.131	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Idarubicin—breast cancer	0.000231	0.131	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Idarubicin—breast cancer	0.000231	0.131	CbGdCrCtD
Imatinib—CYP3A7—endocrine gland—breast cancer	0.00023	0.00474	CbGeAlD
Imatinib—CSF1R—uterus—breast cancer	0.00023	0.00473	CbGeAlD
Imatinib—NQO2—adrenal gland—breast cancer	0.00023	0.00473	CbGeAlD
Imatinib—PDGFRA—adrenal gland—breast cancer	0.000229	0.00472	CbGeAlD
Imatinib—SLC47A1—endometrium—breast cancer	0.000228	0.00469	CbGeAlD
Imatinib—CYP2C9—mammary gland—breast cancer	0.000227	0.00469	CbGeAlD
Imatinib—KIT—endometrium—breast cancer	0.000226	0.00467	CbGeAlD
Imatinib—CSF1R—pituitary gland—breast cancer	0.000226	0.00465	CbGeAlD
Imatinib—CSF1R—adipose tissue—breast cancer	0.000225	0.00463	CbGeAlD
Imatinib—CA2—nipple—breast cancer	0.000222	0.00458	CbGeAlD
Imatinib—NQO2—bone marrow—breast cancer	0.000222	0.00458	CbGeAlD
Imatinib—PDGFRB—endometrium—breast cancer	0.000221	0.00456	CbGeAlD
Imatinib—Ponatinib—KDR—breast cancer	0.000219	0.0547	CrCbGaD
Imatinib—CA12—female reproductive system—breast cancer	0.000217	0.00446	CbGeAlD
Imatinib—NQO2—female gonad—breast cancer	0.000214	0.00441	CbGeAlD
Imatinib—PDGFRA—female gonad—breast cancer	0.000213	0.0044	CbGeAlD
Imatinib—SLC47A1—uterus—breast cancer	0.00021	0.00432	CbGeAlD
Imatinib—ABL1—skin of body—breast cancer	0.000209	0.00431	CbGeAlD
Imatinib—KIT—uterus—breast cancer	0.000209	0.0043	CbGeAlD
Imatinib—ORM1—endometrium—breast cancer	0.000207	0.00427	CbGeAlD
Imatinib—Ponatinib—KIT—breast cancer	0.000207	0.0516	CrCbGaD
Imatinib—CSF1R—female reproductive system—breast cancer	0.000207	0.00426	CbGeAlD
Imatinib—SLC47A1—pituitary gland—breast cancer	0.000206	0.00425	CbGeAlD
Imatinib—SLC47A1—adipose tissue—breast cancer	0.000205	0.00423	CbGeAlD
Imatinib—KIT—pituitary gland—breast cancer	0.000205	0.00422	CbGeAlD
Imatinib—KIT—adipose tissue—breast cancer	0.000204	0.0042	CbGeAlD
Imatinib—PDGFRB—uterus—breast cancer	0.000204	0.0042	CbGeAlD
Imatinib—CSF1R—adrenal gland—breast cancer	0.000202	0.00415	CbGeAlD
Imatinib—PDGFRB—pituitary gland—breast cancer	0.0002	0.00412	CbGeAlD
Imatinib—PDGFRB—adipose tissue—breast cancer	0.000199	0.00411	CbGeAlD
Imatinib—NQO2—endocrine gland—breast cancer	0.000199	0.0041	CbGeAlD
Imatinib—PDGFRA—endocrine gland—breast cancer	0.000199	0.00409	CbGeAlD
Imatinib—CYP1A2—nipple—breast cancer	0.000198	0.00408	CbGeAlD
Imatinib—ABL2—lymph node—breast cancer	0.000198	0.00408	CbGeAlD
Imatinib—ABL1—endometrium—breast cancer	0.000197	0.00406	CbGeAlD
Imatinib—CSF1R—bone marrow—breast cancer	0.000195	0.00402	CbGeAlD
Imatinib—Nilotinib—ABL1—breast cancer	0.00019	0.0475	CrCbGaD
Imatinib—Nilotinib—BRAF—breast cancer	0.00019	0.0475	CrCbGaD
Imatinib—SLC47A1—female reproductive system—breast cancer	0.000189	0.00389	CbGeAlD
Imatinib—CSF1R—female gonad—breast cancer	0.000188	0.00387	CbGeAlD
Imatinib—KIT—female reproductive system—breast cancer	0.000188	0.00387	CbGeAlD
Imatinib—PIP4K2C—lymph node—breast cancer	0.000187	0.00386	CbGeAlD
Imatinib—CA1—adipose tissue—breast cancer	0.000187	0.00385	CbGeAlD
Imatinib—SLC47A1—adrenal gland—breast cancer	0.000184	0.00379	CbGeAlD
Imatinib—CA2—embryo—breast cancer	0.000183	0.00378	CbGeAlD
Imatinib—CA12—endocrine gland—breast cancer	0.000183	0.00378	CbGeAlD
Imatinib—PDGFRB—female reproductive system—breast cancer	0.000183	0.00378	CbGeAlD
Imatinib—KIT—adrenal gland—breast cancer	0.000183	0.00377	CbGeAlD
Imatinib—ABL1—uterus—breast cancer	0.000182	0.00374	CbGeAlD
Imatinib—CA3—lymph node—breast cancer	0.000179	0.00369	CbGeAlD
Imatinib—PDGFRB—adrenal gland—breast cancer	0.000179	0.00368	CbGeAlD
Imatinib—ABL1—pituitary gland—breast cancer	0.000178	0.00368	CbGeAlD
Imatinib—ABL1—adipose tissue—breast cancer	0.000178	0.00366	CbGeAlD
Imatinib—KIT—bone marrow—breast cancer	0.000177	0.00365	CbGeAlD
Imatinib—CSF1R—endocrine gland—breast cancer	0.000175	0.0036	CbGeAlD
Imatinib—PDGFRB—bone marrow—breast cancer	0.000173	0.00356	CbGeAlD
Imatinib—ORM1—female reproductive system—breast cancer	0.000172	0.00354	CbGeAlD
Imatinib—PTGS1—nipple—breast cancer	0.000172	0.00354	CbGeAlD
Imatinib—SLC47A1—female gonad—breast cancer	0.000172	0.00354	CbGeAlD
Imatinib—CA1—female reproductive system—breast cancer	0.000172	0.00354	CbGeAlD
Imatinib—SLC22A1—adipose tissue—breast cancer	0.000171	0.00353	CbGeAlD
Imatinib—KIT—female gonad—breast cancer	0.000171	0.00352	CbGeAlD
Imatinib—PDGFRB—female gonad—breast cancer	0.000167	0.00344	CbGeAlD
Imatinib—LCK—lymph node—breast cancer	0.000166	0.00343	CbGeAlD
Imatinib—ABL1—female reproductive system—breast cancer	0.000163	0.00336	CbGeAlD
Imatinib—ORM1—bone marrow—breast cancer	0.000162	0.00334	CbGeAlD
Imatinib—CA1—bone marrow—breast cancer	0.000162	0.00334	CbGeAlD
Imatinib—SLC47A1—endocrine gland—breast cancer	0.00016	0.00329	CbGeAlD
Imatinib—ABL1—adrenal gland—breast cancer	0.000159	0.00328	CbGeAlD
Imatinib—KIT—endocrine gland—breast cancer	0.000159	0.00327	CbGeAlD
Imatinib—PDGFRB—endocrine gland—breast cancer	0.000155	0.00319	CbGeAlD
Imatinib—ABL1—bone marrow—breast cancer	0.000154	0.00318	CbGeAlD
Imatinib—Nilotinib—KIT—breast cancer	0.000153	0.0381	CrCbGaD
Imatinib—CA2—epithelium—breast cancer	0.00015	0.00308	CbGeAlD
Imatinib—ABL1—female gonad—breast cancer	0.000149	0.00306	CbGeAlD
Imatinib—ALB—adrenal gland—breast cancer	0.000147	0.00303	CbGeAlD
Imatinib—Nilotinib—CA9—breast cancer	0.000147	0.0366	CrCbGaD
Imatinib—ORM1—endocrine gland—breast cancer	0.000145	0.003	CbGeAlD
Imatinib—CA1—endocrine gland—breast cancer	0.000145	0.00299	CbGeAlD
Imatinib—CA2—skin of body—breast cancer	0.000142	0.00293	CbGeAlD
Imatinib—ABL1—endocrine gland—breast cancer	0.000138	0.00285	CbGeAlD
Imatinib—NQO2—lymph node—breast cancer	0.000138	0.00284	CbGeAlD
Imatinib—PDGFRA—lymph node—breast cancer	0.000137	0.00283	CbGeAlD
Imatinib—SLC22A1—endocrine gland—breast cancer	0.000133	0.00274	CbGeAlD
Imatinib—ABCG2—endometrium—breast cancer	0.000124	0.00256	CbGeAlD
Imatinib—CA2—pituitary gland—breast cancer	0.000121	0.0025	CbGeAlD
Imatinib—CA2—adipose tissue—breast cancer	0.000121	0.00249	CbGeAlD
Imatinib—CSF1R—lymph node—breast cancer	0.000121	0.00249	CbGeAlD
Imatinib—PTGS1—epithelium—breast cancer	0.000116	0.00238	CbGeAlD
Imatinib—ABCG2—uterus—breast cancer	0.000115	0.00236	CbGeAlD
Imatinib—Ponatinib—ABCG2—breast cancer	0.000114	0.0286	CrCbGaD
Imatinib—ABCG2—pituitary gland—breast cancer	0.000112	0.00232	CbGeAlD
Imatinib—ABCG2—adipose tissue—breast cancer	0.000112	0.00231	CbGeAlD
Imatinib—CA2—female reproductive system—breast cancer	0.000111	0.00229	CbGeAlD
Imatinib—SLC47A1—lymph node—breast cancer	0.00011	0.00227	CbGeAlD
Imatinib—PTGS1—skin of body—breast cancer	0.00011	0.00227	CbGeAlD
Imatinib—KIT—lymph node—breast cancer	0.00011	0.00226	CbGeAlD
Imatinib—CA2—adrenal gland—breast cancer	0.000108	0.00224	CbGeAlD
Imatinib—PDGFRB—lymph node—breast cancer	0.000107	0.00221	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—breast cancer	0.000106	0.0604	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—breast cancer	0.000106	0.0604	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—breast cancer	0.000106	0.0604	CbGdCrCtD
Imatinib—CA2—bone marrow—breast cancer	0.000105	0.00216	CbGeAlD
Imatinib—CYP3A5—adipose tissue—breast cancer	0.000104	0.00214	CbGeAlD
Imatinib—PTGS1—endometrium—breast cancer	0.000104	0.00214	CbGeAlD
Imatinib—CYP2C19—endocrine gland—breast cancer	0.000103	0.00212	CbGeAlD
Imatinib—CA2—female gonad—breast cancer	0.000101	0.00208	CbGeAlD
Imatinib—ORM1—lymph node—breast cancer	0.000101	0.00207	CbGeAlD
Imatinib—ABCG2—adrenal gland—breast cancer	0.0001	0.00207	CbGeAlD
Imatinib—CA1—lymph node—breast cancer	0.0001	0.00207	CbGeAlD
Imatinib—ABL1—Idarubicin—Doxorubicin—breast cancer	9.79e-05	0.0559	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	9.79e-05	0.0559	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Doxorubicin—breast cancer	9.79e-05	0.0559	CbGdCrCtD
Imatinib—ABCG2—bone marrow—breast cancer	9.72e-05	0.002	CbGeAlD
Imatinib—PTGS1—uterus—breast cancer	9.55e-05	0.00197	CbGeAlD
Imatinib—ABL1—lymph node—breast cancer	9.55e-05	0.00197	CbGeAlD
Imatinib—CA2—endocrine gland—breast cancer	9.41e-05	0.00194	CbGeAlD
Imatinib—CYP2C9—female reproductive system—breast cancer	9.41e-05	0.00194	CbGeAlD
Imatinib—PTGS1—pituitary gland—breast cancer	9.38e-05	0.00193	CbGeAlD
Imatinib—ABCG2—female gonad—breast cancer	9.37e-05	0.00193	CbGeAlD
Imatinib—PTGS1—adipose tissue—breast cancer	9.34e-05	0.00193	CbGeAlD
Imatinib—ALB—lymph node—breast cancer	8.81e-05	0.00182	CbGeAlD
Imatinib—CYP3A5—female gonad—breast cancer	8.7e-05	0.00179	CbGeAlD
Imatinib—PTGS1—female reproductive system—breast cancer	8.59e-05	0.00177	CbGeAlD
Imatinib—Nilotinib—ABCG2—breast cancer	8.44e-05	0.0211	CrCbGaD
Imatinib—CYP1A2—endocrine gland—breast cancer	8.39e-05	0.00173	CbGeAlD
Imatinib—PTGS1—adrenal gland—breast cancer	8.38e-05	0.00173	CbGeAlD
Imatinib—ABCB1—embryo—breast cancer	8.38e-05	0.00173	CbGeAlD
Imatinib—CYP3A5—endocrine gland—breast cancer	8.09e-05	0.00167	CbGeAlD
Imatinib—CYP2C9—endocrine gland—breast cancer	7.96e-05	0.00164	CbGeAlD
Imatinib—PTGS1—female gonad—breast cancer	7.81e-05	0.00161	CbGeAlD
Imatinib—PTGS1—endocrine gland—breast cancer	7.27e-05	0.0015	CbGeAlD
Imatinib—CYP3A4—female reproductive system—breast cancer	7.17e-05	0.00148	CbGeAlD
Imatinib—CYP2D6—female reproductive system—breast cancer	7.06e-05	0.00145	CbGeAlD
Imatinib—ABCB1—epithelium—breast cancer	6.83e-05	0.00141	CbGeAlD
Imatinib—Ponatinib—CYP2D6—breast cancer	6.67e-05	0.0167	CrCbGaD
Imatinib—CA2—lymph node—breast cancer	6.5e-05	0.00134	CbGeAlD
Imatinib—CYP2D6—female gonad—breast cancer	6.42e-05	0.00132	CbGeAlD
Imatinib—ABCB1—endometrium—breast cancer	6.13e-05	0.00126	CbGeAlD
Imatinib—CYP3A4—endocrine gland—breast cancer	6.07e-05	0.00125	CbGeAlD
Imatinib—ABCG2—lymph node—breast cancer	6.02e-05	0.00124	CbGeAlD
Imatinib—CYP2D6—endocrine gland—breast cancer	5.97e-05	0.00123	CbGeAlD
Imatinib—Ponatinib—CYP3A4—breast cancer	5.72e-05	0.0143	CrCbGaD
Imatinib—ABCB1—uterus—breast cancer	5.65e-05	0.00116	CbGeAlD
Imatinib—ABCB1—pituitary gland—breast cancer	5.55e-05	0.00114	CbGeAlD
Imatinib—ABCB1—adipose tissue—breast cancer	5.52e-05	0.00114	CbGeAlD
Imatinib—ABCB1—female reproductive system—breast cancer	5.08e-05	0.00105	CbGeAlD
Imatinib—PTGS1—lymph node—breast cancer	5.02e-05	0.00104	CbGeAlD
Imatinib—ABCB1—adrenal gland—breast cancer	4.95e-05	0.00102	CbGeAlD
Imatinib—Nilotinib—CYP2D6—breast cancer	4.92e-05	0.0123	CrCbGaD
Imatinib—ABCB1—bone marrow—breast cancer	4.79e-05	0.000988	CbGeAlD
Imatinib—Ponatinib—ABCB1—breast cancer	4.76e-05	0.0119	CrCbGaD
Imatinib—ABCB1—female gonad—breast cancer	4.62e-05	0.000952	CbGeAlD
Imatinib—ABCB1—endocrine gland—breast cancer	4.3e-05	0.000885	CbGeAlD
Imatinib—Nilotinib—CYP3A4—breast cancer	4.22e-05	0.0105	CrCbGaD
Imatinib—Nilotinib—ABCB1—breast cancer	3.51e-05	0.00878	CrCbGaD
Imatinib—ABCB1—lymph node—breast cancer	2.97e-05	0.000612	CbGeAlD
Imatinib—Oedema peripheral—Doxorubicin—breast cancer	1.21e-05	8.77e-05	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—breast cancer	1.21e-05	8.77e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.21e-05	8.75e-05	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—breast cancer	1.21e-05	8.75e-05	CcSEcCtD
Imatinib—Dyspnoea—Capecitabine—breast cancer	1.21e-05	8.75e-05	CcSEcCtD
Imatinib—Fatigue—Docetaxel—breast cancer	1.21e-05	8.74e-05	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—breast cancer	1.21e-05	8.73e-05	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—breast cancer	1.21e-05	8.73e-05	CcSEcCtD
Imatinib—Nausea—Mitoxantrone—breast cancer	1.21e-05	8.71e-05	CcSEcCtD
Imatinib—Nausea—Irinotecan—breast cancer	1.21e-05	8.71e-05	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—breast cancer	1.2e-05	8.69e-05	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—breast cancer	1.2e-05	8.68e-05	CcSEcCtD
Imatinib—Pain—Docetaxel—breast cancer	1.2e-05	8.67e-05	CcSEcCtD
Imatinib—Constipation—Docetaxel—breast cancer	1.2e-05	8.67e-05	CcSEcCtD
Imatinib—Back pain—Methotrexate—breast cancer	1.2e-05	8.66e-05	CcSEcCtD
Imatinib—Dyspepsia—Capecitabine—breast cancer	1.2e-05	8.64e-05	CcSEcCtD
Imatinib—Chills—Epirubicin—breast cancer	1.2e-05	8.64e-05	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—breast cancer	1.19e-05	8.6e-05	CcSEcCtD
Imatinib—Asthenia—Paclitaxel—breast cancer	1.19e-05	8.58e-05	CcSEcCtD
Imatinib—Decreased appetite—Capecitabine—breast cancer	1.18e-05	8.53e-05	CcSEcCtD
Imatinib—Alopecia—Epirubicin—breast cancer	1.18e-05	8.51e-05	CcSEcCtD
Imatinib—Nausea—Gemcitabine—breast cancer	1.17e-05	8.49e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.17e-05	8.48e-05	CcSEcCtD
Imatinib—Fatigue—Capecitabine—breast cancer	1.17e-05	8.46e-05	CcSEcCtD
Imatinib—Pruritus—Paclitaxel—breast cancer	1.17e-05	8.46e-05	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—breast cancer	1.17e-05	8.44e-05	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—breast cancer	1.17e-05	8.43e-05	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—breast cancer	1.17e-05	8.42e-05	CcSEcCtD
Imatinib—Pain—Capecitabine—breast cancer	1.16e-05	8.39e-05	CcSEcCtD
Imatinib—Constipation—Capecitabine—breast cancer	1.16e-05	8.39e-05	CcSEcCtD
Imatinib—Erythema—Epirubicin—breast cancer	1.16e-05	8.38e-05	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—breast cancer	1.16e-05	8.38e-05	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—breast cancer	1.16e-05	8.36e-05	CcSEcCtD
Imatinib—Nausea—Fluorouracil—breast cancer	1.15e-05	8.34e-05	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—breast cancer	1.15e-05	8.32e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—breast cancer	1.15e-05	8.31e-05	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—breast cancer	1.15e-05	8.3e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—breast cancer	1.15e-05	8.29e-05	CcSEcCtD
Imatinib—Anaemia—Methotrexate—breast cancer	1.15e-05	8.28e-05	CcSEcCtD
Imatinib—Flushing—Doxorubicin—breast cancer	1.14e-05	8.27e-05	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—breast cancer	1.14e-05	8.27e-05	CcSEcCtD
Imatinib—Flatulence—Epirubicin—breast cancer	1.14e-05	8.26e-05	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—breast cancer	1.14e-05	8.21e-05	CcSEcCtD
Imatinib—Diarrhoea—Paclitaxel—breast cancer	1.13e-05	8.18e-05	CcSEcCtD
Imatinib—Back pain—Epirubicin—breast cancer	1.12e-05	8.11e-05	CcSEcCtD
Imatinib—Feeling abnormal—Capecitabine—breast cancer	1.12e-05	8.09e-05	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—breast cancer	1.12e-05	8.08e-05	CcSEcCtD
Imatinib—Malaise—Methotrexate—breast cancer	1.12e-05	8.07e-05	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—breast cancer	1.12e-05	8.06e-05	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—breast cancer	1.11e-05	8.04e-05	CcSEcCtD
Imatinib—Vertigo—Methotrexate—breast cancer	1.11e-05	8.04e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Capecitabine—breast cancer	1.11e-05	8.03e-05	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—breast cancer	1.11e-05	8.03e-05	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—breast cancer	1.11e-05	8.02e-05	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—breast cancer	1.11e-05	8.02e-05	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—breast cancer	1.11e-05	8.01e-05	CcSEcCtD
Imatinib—Chills—Doxorubicin—breast cancer	1.11e-05	7.99e-05	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—breast cancer	1.1e-05	7.96e-05	CcSEcCtD
Imatinib—Dizziness—Paclitaxel—breast cancer	1.09e-05	7.91e-05	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—breast cancer	1.09e-05	7.9e-05	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—breast cancer	1.09e-05	7.87e-05	CcSEcCtD
Imatinib—Cough—Methotrexate—breast cancer	1.08e-05	7.81e-05	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—breast cancer	1.08e-05	7.8e-05	CcSEcCtD
Imatinib—Urticaria—Capecitabine—breast cancer	1.08e-05	7.8e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—breast cancer	1.08e-05	7.77e-05	CcSEcCtD
Imatinib—Body temperature increased—Capecitabine—breast cancer	1.07e-05	7.76e-05	CcSEcCtD
Imatinib—Abdominal pain—Capecitabine—breast cancer	1.07e-05	7.76e-05	CcSEcCtD
Imatinib—Convulsion—Methotrexate—breast cancer	1.07e-05	7.76e-05	CcSEcCtD
Imatinib—Erythema—Doxorubicin—breast cancer	1.07e-05	7.75e-05	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—breast cancer	1.07e-05	7.75e-05	CcSEcCtD
Imatinib—Anaemia—Epirubicin—breast cancer	1.07e-05	7.74e-05	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—breast cancer	1.06e-05	7.64e-05	CcSEcCtD
Imatinib—Myalgia—Methotrexate—breast cancer	1.06e-05	7.62e-05	CcSEcCtD
Imatinib—Chest pain—Methotrexate—breast cancer	1.06e-05	7.62e-05	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—breast cancer	1.06e-05	7.62e-05	CcSEcCtD
Imatinib—Vomiting—Paclitaxel—breast cancer	1.05e-05	7.61e-05	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—breast cancer	1.05e-05	7.59e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.05e-05	7.57e-05	CcSEcCtD
Imatinib—Malaise—Epirubicin—breast cancer	1.05e-05	7.56e-05	CcSEcCtD
Imatinib—Rash—Paclitaxel—breast cancer	1.04e-05	7.54e-05	CcSEcCtD
Imatinib—Dermatitis—Paclitaxel—breast cancer	1.04e-05	7.54e-05	CcSEcCtD
Imatinib—Discomfort—Methotrexate—breast cancer	1.04e-05	7.53e-05	CcSEcCtD
Imatinib—Vertigo—Epirubicin—breast cancer	1.04e-05	7.53e-05	CcSEcCtD
Imatinib—Syncope—Epirubicin—breast cancer	1.04e-05	7.51e-05	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—breast cancer	1.04e-05	7.5e-05	CcSEcCtD
Imatinib—Back pain—Doxorubicin—breast cancer	1.04e-05	7.5e-05	CcSEcCtD
Imatinib—Headache—Paclitaxel—breast cancer	1.04e-05	7.49e-05	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—breast cancer	1.03e-05	7.47e-05	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—breast cancer	1.03e-05	7.45e-05	CcSEcCtD
Imatinib—Palpitations—Epirubicin—breast cancer	1.02e-05	7.41e-05	CcSEcCtD
Imatinib—Confusional state—Methotrexate—breast cancer	1.02e-05	7.37e-05	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—breast cancer	1.02e-05	7.36e-05	CcSEcCtD
Imatinib—Cough—Epirubicin—breast cancer	1.01e-05	7.31e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—breast cancer	1.01e-05	7.31e-05	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—breast cancer	1.01e-05	7.31e-05	CcSEcCtD
Imatinib—Asthenia—Docetaxel—breast cancer	1.01e-05	7.27e-05	CcSEcCtD
Imatinib—Convulsion—Epirubicin—breast cancer	1e-05	7.26e-05	CcSEcCtD
Imatinib—Infection—Methotrexate—breast cancer	1e-05	7.26e-05	CcSEcCtD
Imatinib—Hypertension—Epirubicin—breast cancer	1e-05	7.23e-05	CcSEcCtD
Imatinib—Hypersensitivity—Capecitabine—breast cancer	1e-05	7.23e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—breast cancer	9.96e-06	7.19e-05	CcSEcCtD
Imatinib—Pruritus—Docetaxel—breast cancer	9.93e-06	7.17e-05	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—breast cancer	9.92e-06	7.17e-05	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—breast cancer	9.92e-06	7.17e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—breast cancer	9.9e-06	7.16e-05	CcSEcCtD
Imatinib—Chest pain—Epirubicin—breast cancer	9.87e-06	7.13e-05	CcSEcCtD
Imatinib—Myalgia—Epirubicin—breast cancer	9.87e-06	7.13e-05	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—breast cancer	9.87e-06	7.13e-05	CcSEcCtD
Imatinib—Anxiety—Epirubicin—breast cancer	9.84e-06	7.11e-05	CcSEcCtD
Imatinib—Nausea—Paclitaxel—breast cancer	9.83e-06	7.11e-05	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—breast cancer	9.82e-06	7.1e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	9.81e-06	7.08e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—breast cancer	9.78e-06	7.06e-05	CcSEcCtD
Imatinib—Discomfort—Epirubicin—breast cancer	9.76e-06	7.05e-05	CcSEcCtD
Imatinib—Asthenia—Capecitabine—breast cancer	9.75e-06	7.04e-05	CcSEcCtD
Imatinib—Malaise—Doxorubicin—breast cancer	9.68e-06	6.99e-05	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—breast cancer	9.66e-06	6.98e-05	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—breast cancer	9.64e-06	6.97e-05	CcSEcCtD
Imatinib—Anorexia—Methotrexate—breast cancer	9.64e-06	6.97e-05	CcSEcCtD
Imatinib—Syncope—Doxorubicin—breast cancer	9.62e-06	6.95e-05	CcSEcCtD
Imatinib—Pruritus—Capecitabine—breast cancer	9.61e-06	6.95e-05	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—breast cancer	9.61e-06	6.94e-05	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—breast cancer	9.6e-06	6.94e-05	CcSEcCtD
Imatinib—Confusional state—Epirubicin—breast cancer	9.54e-06	6.9e-05	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—breast cancer	9.48e-06	6.85e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—breast cancer	9.47e-06	6.84e-05	CcSEcCtD
Imatinib—Oedema—Epirubicin—breast cancer	9.47e-06	6.84e-05	CcSEcCtD
Imatinib—Hypotension—Methotrexate—breast cancer	9.45e-06	6.83e-05	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—breast cancer	9.43e-06	6.81e-05	CcSEcCtD
Imatinib—Infection—Epirubicin—breast cancer	9.4e-06	6.79e-05	CcSEcCtD
Imatinib—Cough—Doxorubicin—breast cancer	9.36e-06	6.77e-05	CcSEcCtD
Imatinib—Shock—Epirubicin—breast cancer	9.31e-06	6.73e-05	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—breast cancer	9.3e-06	6.72e-05	CcSEcCtD
Imatinib—Diarrhoea—Capecitabine—breast cancer	9.3e-06	6.72e-05	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—breast cancer	9.28e-06	6.71e-05	CcSEcCtD
Imatinib—Dizziness—Docetaxel—breast cancer	9.28e-06	6.7e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—breast cancer	9.27e-06	6.7e-05	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—breast cancer	9.26e-06	6.69e-05	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—breast cancer	9.24e-06	6.67e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—breast cancer	9.21e-06	6.66e-05	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—breast cancer	9.19e-06	6.64e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—breast cancer	9.15e-06	6.61e-05	CcSEcCtD
Imatinib—Insomnia—Methotrexate—breast cancer	9.15e-06	6.61e-05	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—breast cancer	9.14e-06	6.6e-05	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—breast cancer	9.14e-06	6.6e-05	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—breast cancer	9.14e-06	6.6e-05	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—breast cancer	9.1e-06	6.58e-05	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—breast cancer	9.08e-06	6.56e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.07e-06	6.56e-05	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—breast cancer	9.03e-06	6.52e-05	CcSEcCtD
Imatinib—Anorexia—Epirubicin—breast cancer	9.02e-06	6.52e-05	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—breast cancer	9.02e-06	6.52e-05	CcSEcCtD
Imatinib—Somnolence—Methotrexate—breast cancer	8.99e-06	6.5e-05	CcSEcCtD
Imatinib—Dizziness—Capecitabine—breast cancer	8.98e-06	6.49e-05	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—breast cancer	8.93e-06	6.46e-05	CcSEcCtD
Imatinib—Vomiting—Docetaxel—breast cancer	8.92e-06	6.45e-05	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—breast cancer	8.9e-06	6.43e-05	CcSEcCtD
Imatinib—Rash—Docetaxel—breast cancer	8.85e-06	6.39e-05	CcSEcCtD
Imatinib—Hypotension—Epirubicin—breast cancer	8.84e-06	6.39e-05	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—breast cancer	8.84e-06	6.39e-05	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—breast cancer	8.83e-06	6.38e-05	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—breast cancer	8.79e-06	6.35e-05	CcSEcCtD
Imatinib—Headache—Docetaxel—breast cancer	8.79e-06	6.35e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—breast cancer	8.76e-06	6.33e-05	CcSEcCtD
Imatinib—Oedema—Doxorubicin—breast cancer	8.76e-06	6.33e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—breast cancer	8.73e-06	6.31e-05	CcSEcCtD
Imatinib—Fatigue—Methotrexate—breast cancer	8.72e-06	6.3e-05	CcSEcCtD
Imatinib—Infection—Doxorubicin—breast cancer	8.7e-06	6.29e-05	CcSEcCtD
Imatinib—Pain—Methotrexate—breast cancer	8.65e-06	6.25e-05	CcSEcCtD
Imatinib—Vomiting—Capecitabine—breast cancer	8.64e-06	6.24e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—breast cancer	8.62e-06	6.23e-05	CcSEcCtD
Imatinib—Shock—Doxorubicin—breast cancer	8.62e-06	6.23e-05	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—breast cancer	8.59e-06	6.21e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—breast cancer	8.57e-06	6.2e-05	CcSEcCtD
Imatinib—Rash—Capecitabine—breast cancer	8.57e-06	6.19e-05	CcSEcCtD
Imatinib—Insomnia—Epirubicin—breast cancer	8.56e-06	6.19e-05	CcSEcCtD
Imatinib—Dermatitis—Capecitabine—breast cancer	8.56e-06	6.18e-05	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—breast cancer	8.55e-06	6.18e-05	CcSEcCtD
Imatinib—Headache—Capecitabine—breast cancer	8.51e-06	6.15e-05	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—breast cancer	8.51e-06	6.15e-05	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—breast cancer	8.5e-06	6.14e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—breast cancer	8.47e-06	6.12e-05	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—breast cancer	8.44e-06	6.1e-05	CcSEcCtD
Imatinib—Somnolence—Epirubicin—breast cancer	8.41e-06	6.08e-05	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—breast cancer	8.35e-06	6.03e-05	CcSEcCtD
Imatinib—Nausea—Docetaxel—breast cancer	8.34e-06	6.02e-05	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—breast cancer	8.33e-06	6.02e-05	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—breast cancer	8.33e-06	6.02e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—breast cancer	8.27e-06	5.98e-05	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—breast cancer	8.23e-06	5.94e-05	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—breast cancer	8.18e-06	5.91e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—breast cancer	8.17e-06	5.9e-05	CcSEcCtD
Imatinib—Fatigue—Epirubicin—breast cancer	8.16e-06	5.9e-05	CcSEcCtD
Imatinib—Pain—Epirubicin—breast cancer	8.09e-06	5.85e-05	CcSEcCtD
Imatinib—Constipation—Epirubicin—breast cancer	8.09e-06	5.85e-05	CcSEcCtD
Imatinib—Nausea—Capecitabine—breast cancer	8.07e-06	5.83e-05	CcSEcCtD
Imatinib—Urticaria—Methotrexate—breast cancer	8.03e-06	5.81e-05	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—breast cancer	8e-06	5.78e-05	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—breast cancer	8e-06	5.78e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.98e-06	5.77e-05	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—breast cancer	7.92e-06	5.72e-05	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—breast cancer	7.86e-06	5.68e-05	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—breast cancer	7.81e-06	5.64e-05	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—breast cancer	7.8e-06	5.64e-05	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—breast cancer	7.79e-06	5.63e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—breast cancer	7.74e-06	5.59e-05	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—breast cancer	7.71e-06	5.57e-05	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—breast cancer	7.61e-06	5.5e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—breast cancer	7.56e-06	5.46e-05	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—breast cancer	7.55e-06	5.46e-05	CcSEcCtD
Imatinib—Urticaria—Epirubicin—breast cancer	7.52e-06	5.43e-05	CcSEcCtD
Imatinib—Constipation—Doxorubicin—breast cancer	7.49e-06	5.41e-05	CcSEcCtD
Imatinib—Pain—Doxorubicin—breast cancer	7.49e-06	5.41e-05	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—breast cancer	7.48e-06	5.41e-05	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—breast cancer	7.48e-06	5.41e-05	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—breast cancer	7.45e-06	5.38e-05	CcSEcCtD
Imatinib—Asthenia—Methotrexate—breast cancer	7.26e-06	5.24e-05	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—breast cancer	7.22e-06	5.21e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—breast cancer	7.16e-06	5.17e-05	CcSEcCtD
Imatinib—Pruritus—Methotrexate—breast cancer	7.16e-06	5.17e-05	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—breast cancer	6.97e-06	5.04e-05	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—breast cancer	6.96e-06	5.03e-05	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—breast cancer	6.92e-06	5e-05	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—breast cancer	6.92e-06	5e-05	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—breast cancer	6.92e-06	5e-05	CcSEcCtD
Imatinib—Asthenia—Epirubicin—breast cancer	6.79e-06	4.91e-05	CcSEcCtD
Imatinib—Pruritus—Epirubicin—breast cancer	6.7e-06	4.84e-05	CcSEcCtD
Imatinib—Dizziness—Methotrexate—breast cancer	6.69e-06	4.83e-05	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—breast cancer	6.48e-06	4.68e-05	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—breast cancer	6.45e-06	4.66e-05	CcSEcCtD
Imatinib—Vomiting—Methotrexate—breast cancer	6.43e-06	4.65e-05	CcSEcCtD
Imatinib—Rash—Methotrexate—breast cancer	6.38e-06	4.61e-05	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—breast cancer	6.37e-06	4.6e-05	CcSEcCtD
Imatinib—Headache—Methotrexate—breast cancer	6.34e-06	4.58e-05	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—breast cancer	6.28e-06	4.54e-05	CcSEcCtD
Imatinib—Dizziness—Epirubicin—breast cancer	6.26e-06	4.52e-05	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—breast cancer	6.2e-06	4.48e-05	CcSEcCtD
Imatinib—Vomiting—Epirubicin—breast cancer	6.02e-06	4.35e-05	CcSEcCtD
Imatinib—Nausea—Methotrexate—breast cancer	6.01e-06	4.34e-05	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—breast cancer	5.99e-06	4.33e-05	CcSEcCtD
Imatinib—Rash—Epirubicin—breast cancer	5.97e-06	4.31e-05	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—breast cancer	5.96e-06	4.31e-05	CcSEcCtD
Imatinib—Headache—Epirubicin—breast cancer	5.93e-06	4.28e-05	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—breast cancer	5.79e-06	4.18e-05	CcSEcCtD
Imatinib—Nausea—Epirubicin—breast cancer	5.62e-06	4.06e-05	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—breast cancer	5.57e-06	4.02e-05	CcSEcCtD
Imatinib—Rash—Doxorubicin—breast cancer	5.52e-06	3.99e-05	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—breast cancer	5.52e-06	3.99e-05	CcSEcCtD
Imatinib—Headache—Doxorubicin—breast cancer	5.49e-06	3.96e-05	CcSEcCtD
Imatinib—Nausea—Doxorubicin—breast cancer	5.2e-06	3.76e-05	CcSEcCtD
Imatinib—PDGFRB—Signaling Pathways—MAPK8—breast cancer	5.52e-07	5.29e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—breast cancer	5.5e-07	5.27e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—breast cancer	5.49e-07	5.27e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOA1—breast cancer	5.49e-07	5.27e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—breast cancer	5.48e-07	5.26e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—breast cancer	5.46e-07	5.24e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—breast cancer	5.45e-07	5.22e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—breast cancer	5.45e-07	5.22e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—breast cancer	5.44e-07	5.22e-06	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—breast cancer	5.44e-07	5.22e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—breast cancer	5.43e-07	5.21e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NCOR1—breast cancer	5.43e-07	5.21e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLA2G4A—breast cancer	5.43e-07	5.21e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ERCC2—breast cancer	5.42e-07	5.2e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—breast cancer	5.41e-07	5.19e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—STK11—breast cancer	5.41e-07	5.19e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLA2G4A—breast cancer	5.39e-07	5.16e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—breast cancer	5.39e-07	5.16e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NCOR1—breast cancer	5.39e-07	5.16e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—breast cancer	5.38e-07	5.16e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—breast cancer	5.37e-07	5.15e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—breast cancer	5.37e-07	5.15e-06	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—breast cancer	5.37e-07	5.15e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—breast cancer	5.36e-07	5.14e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAF1—breast cancer	5.36e-07	5.14e-06	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—breast cancer	5.36e-07	5.14e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—breast cancer	5.35e-07	5.13e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RELA—breast cancer	5.34e-07	5.12e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—breast cancer	5.31e-07	5.09e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—breast cancer	5.31e-07	5.09e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP17A1—breast cancer	5.28e-07	5.06e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—breast cancer	5.26e-07	5.04e-06	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—breast cancer	5.25e-07	5.04e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—breast cancer	5.24e-07	5.03e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—breast cancer	5.24e-07	5.02e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—breast cancer	5.24e-07	5.02e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—breast cancer	5.23e-07	5.01e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO1—breast cancer	5.22e-07	5.01e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS1—breast cancer	5.22e-07	5.01e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—breast cancer	5.22e-07	5e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—breast cancer	5.21e-07	4.99e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—breast cancer	5.2e-07	4.99e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—breast cancer	5.2e-07	4.99e-06	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—breast cancer	5.2e-07	4.99e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—breast cancer	5.2e-07	4.98e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—breast cancer	5.19e-07	4.97e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—breast cancer	5.19e-07	4.97e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—breast cancer	5.16e-07	4.94e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—breast cancer	5.15e-07	4.94e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—breast cancer	5.15e-07	4.94e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.12e-07	4.91e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2D6—breast cancer	5.12e-07	4.91e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ERCC2—breast cancer	5.11e-07	4.9e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—breast cancer	5.1e-07	4.89e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—breast cancer	5.09e-07	4.88e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	5.09e-07	4.88e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—breast cancer	5.09e-07	4.88e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.08e-07	4.87e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—breast cancer	5.08e-07	4.87e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ERCC2—breast cancer	5.06e-07	4.85e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—breast cancer	5.04e-07	4.83e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—breast cancer	5.04e-07	4.83e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—breast cancer	5.03e-07	4.82e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—COMT—breast cancer	5.03e-07	4.82e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—breast cancer	5.03e-07	4.82e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOA2—breast cancer	5.03e-07	4.82e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—breast cancer	5.03e-07	4.82e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—breast cancer	5.01e-07	4.8e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—breast cancer	4.99e-07	4.78e-06	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—breast cancer	4.96e-07	4.76e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—breast cancer	4.94e-07	4.74e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—breast cancer	4.94e-07	4.73e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ITPR1—breast cancer	4.93e-07	4.72e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—breast cancer	4.92e-07	4.72e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—breast cancer	4.91e-07	4.71e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—breast cancer	4.9e-07	4.7e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—breast cancer	4.89e-07	4.68e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—FASN—breast cancer	4.88e-07	4.68e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—breast cancer	4.86e-07	4.66e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—breast cancer	4.84e-07	4.64e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	4.82e-07	4.62e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—breast cancer	4.82e-07	4.62e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—breast cancer	4.81e-07	4.62e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—breast cancer	4.81e-07	4.61e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—breast cancer	4.81e-07	4.61e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—breast cancer	4.8e-07	4.6e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—breast cancer	4.8e-07	4.6e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—breast cancer	4.76e-07	4.56e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—breast cancer	4.74e-07	4.55e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—breast cancer	4.71e-07	4.52e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—breast cancer	4.7e-07	4.51e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—breast cancer	4.69e-07	4.49e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—breast cancer	4.69e-07	4.49e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—breast cancer	4.68e-07	4.49e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	4.67e-07	4.48e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—breast cancer	4.66e-07	4.47e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—breast cancer	4.66e-07	4.46e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—breast cancer	4.64e-07	4.45e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—breast cancer	4.64e-07	4.45e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NQO1—breast cancer	4.63e-07	4.44e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—breast cancer	4.63e-07	4.44e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLA2G4A—breast cancer	4.6e-07	4.41e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOR1—breast cancer	4.6e-07	4.41e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—breast cancer	4.6e-07	4.41e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.6e-07	4.41e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—breast cancer	4.6e-07	4.41e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—breast cancer	4.58e-07	4.39e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—breast cancer	4.57e-07	4.38e-06	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—breast cancer	4.56e-07	4.37e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—breast cancer	4.55e-07	4.36e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—breast cancer	4.53e-07	4.35e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—breast cancer	4.52e-07	4.34e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—breast cancer	4.51e-07	4.33e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1B1—breast cancer	4.44e-07	4.26e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—breast cancer	4.43e-07	4.25e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK8—breast cancer	4.43e-07	4.24e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	4.41e-07	4.23e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—breast cancer	4.41e-07	4.23e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—breast cancer	4.39e-07	4.21e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—breast cancer	4.39e-07	4.2e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—breast cancer	4.37e-07	4.19e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—breast cancer	4.36e-07	4.18e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.36e-07	4.18e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—breast cancer	4.35e-07	4.17e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—breast cancer	4.33e-07	4.15e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ERCC2—breast cancer	4.33e-07	4.15e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—breast cancer	4.32e-07	4.14e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—breast cancer	4.31e-07	4.13e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—breast cancer	4.29e-07	4.12e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—breast cancer	4.28e-07	4.1e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—breast cancer	4.27e-07	4.1e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOA1—breast cancer	4.24e-07	4.06e-06	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—breast cancer	4.22e-07	4.04e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—breast cancer	4.2e-07	4.02e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.19e-07	4.02e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—STK11—breast cancer	4.18e-07	4e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—breast cancer	4.18e-07	4e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—breast cancer	4.13e-07	3.96e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—breast cancer	4.09e-07	3.92e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—breast cancer	4.08e-07	3.92e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—breast cancer	4.07e-07	3.9e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—breast cancer	4.06e-07	3.89e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—breast cancer	4.05e-07	3.88e-06	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—breast cancer	4.04e-07	3.87e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—breast cancer	4.03e-07	3.87e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—breast cancer	4.03e-07	3.87e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—breast cancer	4e-07	3.83e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	3.98e-07	3.81e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—breast cancer	3.91e-07	3.75e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—COMT—breast cancer	3.88e-07	3.72e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—breast cancer	3.87e-07	3.71e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—breast cancer	3.86e-07	3.71e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—breast cancer	3.86e-07	3.7e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—breast cancer	3.85e-07	3.69e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—breast cancer	3.81e-07	3.65e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—breast cancer	3.81e-07	3.65e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—breast cancer	3.81e-07	3.65e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ITPR1—breast cancer	3.8e-07	3.65e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—breast cancer	3.76e-07	3.61e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—breast cancer	3.76e-07	3.61e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—breast cancer	3.76e-07	3.6e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—breast cancer	3.75e-07	3.6e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—breast cancer	3.75e-07	3.6e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—breast cancer	3.74e-07	3.59e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—breast cancer	3.72e-07	3.57e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—breast cancer	3.71e-07	3.56e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—breast cancer	3.71e-07	3.56e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—breast cancer	3.7e-07	3.55e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—breast cancer	3.68e-07	3.53e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—breast cancer	3.68e-07	3.53e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—breast cancer	3.67e-07	3.51e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—breast cancer	3.66e-07	3.51e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—breast cancer	3.66e-07	3.51e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—breast cancer	3.64e-07	3.49e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—breast cancer	3.61e-07	3.46e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—breast cancer	3.59e-07	3.45e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.58e-07	3.44e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—breast cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—breast cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—breast cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOR1—breast cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—breast cancer	3.55e-07	3.4e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—breast cancer	3.52e-07	3.38e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—breast cancer	3.52e-07	3.37e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—breast cancer	3.5e-07	3.36e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—breast cancer	3.47e-07	3.33e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—breast cancer	3.47e-07	3.33e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—breast cancer	3.42e-07	3.28e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—breast cancer	3.41e-07	3.27e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—breast cancer	3.4e-07	3.26e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—breast cancer	3.37e-07	3.23e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—breast cancer	3.36e-07	3.22e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—breast cancer	3.35e-07	3.21e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ERCC2—breast cancer	3.34e-07	3.2e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—breast cancer	3.33e-07	3.19e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—breast cancer	3.32e-07	3.18e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—breast cancer	3.28e-07	3.14e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—breast cancer	3.25e-07	3.12e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—breast cancer	3.25e-07	3.12e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—breast cancer	3.23e-07	3.1e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—breast cancer	3.19e-07	3.06e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—breast cancer	3.14e-07	3.01e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—breast cancer	3.09e-07	2.96e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—breast cancer	3.09e-07	2.96e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—breast cancer	3.06e-07	2.94e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—breast cancer	3.06e-07	2.94e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—breast cancer	3.04e-07	2.91e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—breast cancer	3.02e-07	2.9e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—breast cancer	3e-07	2.88e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—breast cancer	2.99e-07	2.87e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—breast cancer	2.99e-07	2.87e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—breast cancer	2.97e-07	2.84e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—breast cancer	2.95e-07	2.83e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—breast cancer	2.9e-07	2.78e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—breast cancer	2.9e-07	2.78e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—breast cancer	2.9e-07	2.78e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—breast cancer	2.84e-07	2.72e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—breast cancer	2.83e-07	2.72e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—breast cancer	2.83e-07	2.71e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—breast cancer	2.79e-07	2.67e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—breast cancer	2.67e-07	2.56e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—breast cancer	2.65e-07	2.54e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—breast cancer	2.65e-07	2.54e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—breast cancer	2.64e-07	2.53e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—breast cancer	2.62e-07	2.51e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—breast cancer	2.61e-07	2.5e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—breast cancer	2.59e-07	2.49e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—breast cancer	2.32e-07	2.22e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—breast cancer	2.29e-07	2.19e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—breast cancer	2.28e-07	2.19e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—breast cancer	2.26e-07	2.17e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—breast cancer	2.19e-07	2.1e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—breast cancer	2.16e-07	2.08e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—breast cancer	2.05e-07	1.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—breast cancer	2.02e-07	1.94e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—breast cancer	2e-07	1.92e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—breast cancer	2e-07	1.92e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—breast cancer	1.88e-07	1.81e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—breast cancer	1.87e-07	1.79e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—breast cancer	1.86e-07	1.79e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—breast cancer	1.75e-07	1.67e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—breast cancer	1.67e-07	1.6e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—breast cancer	1.63e-07	1.57e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—breast cancer	1.6e-07	1.53e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—breast cancer	1.54e-07	1.48e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—breast cancer	1.53e-07	1.46e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—breast cancer	1.3e-07	1.25e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—breast cancer	1.23e-07	1.18e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—breast cancer	1.01e-07	9.65e-07	CbGpPWpGaD
